Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JP-2266 in Type 2 Diabetes Mellitus
NCT06144788Phase 2Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JP-2266 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoint: Changes in HbA1c at 12 weeks. Started Nov 2023; status: completed.
02
Drugs
JP-2266
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06144788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144788.